文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

立体定向体部放疗对人胰腺导管腺癌免疫微环境的调节作用。

Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy.

机构信息

Department of Surgery, University of Rochester Medical Center, Rochester, New York.

Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York.

出版信息

Clin Cancer Res. 2022 Jan 1;28(1):150-162. doi: 10.1158/1078-0432.CCR-21-2495. Epub 2021 Dec 3.


DOI:10.1158/1078-0432.CCR-21-2495
PMID:34862242
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8738140/
Abstract

PURPOSE: Stereotactic body radiotherapy (SBRT) is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC), which can effectively prime cytotoxic T cells by inducing immunogenic tumor cell death in preclinical models. SBRT effects on human PDAC have yet to be thoroughly investigated; therefore, this study aimed to characterize immunomodulation in the human PDAC tumor microenvironment following therapy. EXPERIMENTAL DESIGN: Tumor samples were obtained from patients with resectable PDAC. Radiotherapy was delivered a median of 7 days prior to surgical resection, and sections were analyzed by multiplex IHC (mIHC), RNA sequencing, and T-cell receptor sequencing (TCR-seq). RESULTS: Analysis of SBRT-treated tumor tissue indicated reduced tumor cell density and increased immunogenic cell death relative to untreated controls. Radiotherapy promoted collagen deposition; however, vasculature was unaffected and spatial analyses lacked evidence of T-cell sequestration. Conversely, SBRT resulted in fewer tertiary lymphoid structures and failed to lessen or reprogram abundant immune suppressor populations. Higher percentages of PD-1 T cells were observed following SBRT, and a subset of tumors displayed more clonal T-cell repertoires. CONCLUSIONS: These findings suggest that SBRT augmentation of antitumor immunogenicity may be dampened by an overabundance of refractory immunosuppressive populations, and support the continued development of SBRT/immunotherapy combination for human PDAC.

摘要

目的:立体定向体部放疗(SBRT)是一种新兴的治疗胰腺导管腺癌(PDAC)的方法,它可以通过在临床前模型中诱导免疫原性肿瘤细胞死亡来有效地激活细胞毒性 T 细胞。SBRT 对人类 PDAC 的影响尚未得到彻底研究;因此,本研究旨在描述治疗后人类 PDAC 肿瘤微环境中的免疫调节作用。

实验设计:从可切除的 PDAC 患者中获得肿瘤样本。放射治疗在手术切除前中位数为 7 天进行,并通过多重免疫组化(mIHC)、RNA 测序和 T 细胞受体测序(TCR-seq)进行分析。

结果:对 SBRT 治疗的肿瘤组织进行分析表明,与未治疗对照相比,肿瘤细胞密度降低,免疫原性细胞死亡增加。放射治疗促进了胶原蛋白的沉积;然而,血管不受影响,空间分析也没有证据表明 T 细胞被隔离。相反,SBRT 导致更少的三级淋巴结构,并且不能减轻或重新编程丰富的免疫抑制群体。SBRT 后观察到更多的 PD-1 T 细胞,并且一部分肿瘤显示出更多的克隆 T 细胞库。

结论:这些发现表明,SBRT 增强抗肿瘤免疫原性的作用可能被过多的难治性免疫抑制群体所抑制,并支持继续开发 SBRT/免疫疗法联合治疗人类 PDAC。

相似文献

[1]
Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy.

Clin Cancer Res. 2022-1-1

[2]
Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.

J Immunother Cancer. 2022-7

[3]
CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.

J Immunother Cancer. 2023-5

[4]
Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.

Pract Radiat Oncol. 2017

[5]
A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE).

Trials. 2022-10-28

[6]
Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.

Oncoimmunology. 2021-3-17

[7]
Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review.

Curr Oncol. 2022-4-11

[8]
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma.

Clin Oncol (R Coll Radiol). 2021-1

[9]
MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).

Radiat Oncol. 2022-1-25

[10]
Radiotherapy for locally advanced pancreatic ductal adenocarcinoma.

Semin Oncol. 2021-2

引用本文的文献

[1]
Review: radiotherapy-mediated B cells within the TLS influence the tumor microenvironment.

J Immunother Cancer. 2025-7-15

[2]
Radiotherapy-induced alterations in tumor microenvironment: metabolism and immunity.

Front Cell Dev Biol. 2025-4-28

[3]
Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma.

J Gastrointest Cancer. 2025-1-18

[4]
Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer.

Mol Cancer Ther. 2025-6-4

[5]
Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity.

Elife. 2024-12-10

[6]
Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer.

Mol Ther Nucleic Acids. 2024-9-30

[7]
Barriers and opportunities in pancreatic cancer immunotherapy.

NPJ Precis Oncol. 2024-9-12

[8]
Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot.

Front Cell Dev Biol. 2024-5-7

[9]
PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.

World J Gastroenterol. 2024-3-7

[10]
The crucial prognostic signaling pathways of pancreatic ductal adenocarcinoma were identified by single-cell and bulk RNA sequencing data.

Hum Genet. 2024-10

本文引用的文献

[1]
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control.

J Clin Invest. 2021-3-1

[2]
Interactions between tumor-derived proteins and Toll-like receptors.

Exp Mol Med. 2020-12

[3]
Ionizing radiation results in a mixture of cellular outcomes including mitotic catastrophe, senescence, methuosis, and iron-dependent cell death.

Cell Death Dis. 2020-11-23

[4]
Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients.

Proc Natl Acad Sci U S A. 2020-9-8

[5]
Immunological combination treatment holds the key to improving survival in pancreatic cancer.

J Cancer Res Clin Oncol. 2020-8-3

[6]
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.

J Natl Cancer Inst. 2021-2-1

[7]
Evolution of the immune landscape during progression of pancreatic intraductal papillary mucinous neoplasms to invasive cancer.

EBioMedicine. 2020-4

[8]
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Clin Cancer Res. 2020-5-15

[9]
Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients.

Cancer Immunol Immunother. 2020-1-2

[10]
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.

Oncologist. 2020-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索